These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15254292)

  • 1. Management of cirrhosis and ascites.
    O'Beirne JP; Foxton MR; Heneghan MA
    N Engl J Med; 2004 Jul; 351(3):300-1; author reply 300-1. PubMed ID: 15254292
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kidney insufficiency in decompensated liver cirrhosis--the so-called hepatorenal syndrome].
    Lange H; Martini GA
    Med Klin; 1974 Apr; 69(14):551-60. PubMed ID: 4600333
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined ascitic-fluid and furosemide infusion in the management of ascites.
    Eknoyan G; Martinez-Maldonado M; Yium JJ; Suki WN
    N Engl J Med; 1970 Mar; 282(13):713-7. PubMed ID: 5416204
    [No Abstract]   [Full Text] [Related]  

  • 4. AKI in a patient with cirrhosis and ascites.
    Davenport A
    Clin J Am Soc Nephrol; 2012 Dec; 7(12):2041-8. PubMed ID: 22977213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of atrial natriuretic factor on renal excretion of sodium in patients with liver cirrhosis].
    Moreau R; Lebrec D
    Gastroenterol Clin Biol; 1994; 18(6-7):568-73. PubMed ID: 7875416
    [No Abstract]   [Full Text] [Related]  

  • 6. Nitric oxide and renal functions in liver cirrhosis.
    Türkay C; Yönem O; Arikan O; Baskin E
    Turk J Gastroenterol; 2004 Jun; 15(2):73-6. PubMed ID: 15334313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for kidney diseases: older measures versus novel biomarkers.
    Wu I; Parikh CR
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1895-901. PubMed ID: 18922990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of renal impairment in Laennec's cirrhosis.
    Mullane JF; Gliedman ML
    Ann Surg; 1971 Dec; 174(6):892-901. PubMed ID: 5316206
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of single dose of 50mg captopril in patients with liver cirrhosis and ascites.
    Lee JK; Hsieh JF; Tsai SC; Ho YJ; Kao CH
    Hepatogastroenterology; 2000; 47(33):767-70. PubMed ID: 10919029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and renal effects of low-dose atrial natriuretic peptide in compensated cirrhosis.
    La Villa G; Lazzeri C; Pascale A; Sestini S; Bisi G; Sciagrà R; Vecchiarino S; Raggi VC; Barletta G; Laffi G; Gentilini P
    Am J Gastroenterol; 1997 May; 92(5):852-7. PubMed ID: 9149200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer.
    Solà E; Ginès P
    Liver Int; 2015 Sep; 35(9):2079-81. PubMed ID: 26053461
    [No Abstract]   [Full Text] [Related]  

  • 12. The effects of decongestion operation on renal haemodynamics in patients with bilharzial hepatic fibrosis and ascites.
    Badawi T; Abu-Zeina A; El-Sawy M; Abdel Fattah MM; Badawi H; Kilany MS; Hassab MA
    J Trop Med Hyg; 1976 Sep; 79(9):201-4. PubMed ID: 1003591
    [No Abstract]   [Full Text] [Related]  

  • 13. [Physiopathology of nephropathy in liver cirrhosis. Pathogenetic role of ascites and of inferior vena cava pressure increase].
    Gatta A; Zuin R; Merkel C; Milani L; Ruol A
    Minerva Dietol Gastroenterol; 1979; 25(1):9-16. PubMed ID: 450267
    [No Abstract]   [Full Text] [Related]  

  • 14. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis.
    Orlando R; Floreani M; Padrini R; Palatini P
    Clin Nephrol; 1999 Jun; 51(6):341-7. PubMed ID: 10404694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of renal function in cirrhotic patients. I. Diuresis and glomerular filtration].
    Solís Herruzo JA
    Rev Clin Esp; 1971 May; 121(4):347-56. PubMed ID: 5563110
    [No Abstract]   [Full Text] [Related]  

  • 18. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements.
    Cholongitas E; Shusang V; Marelli L; Nair D; Thomas M; Patch D; Burns A; Sweny P; Burroughs AK
    Aliment Pharmacol Ther; 2007 Oct; 26(7):969-78. PubMed ID: 17877504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of ascites formation and hepatorenal syndrome: humoral and hemodynamic factors.
    Ring-Larsen H; Henriksen JH
    Semin Liver Dis; 1986 Nov; 6(4):341-52. PubMed ID: 3544227
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pathogenesis of ascites formation in liver cirrhosis (author's transl)].
    Arbeiter G; Meyer-Burg J
    Leber Magen Darm; 1974 Oct; 4(6):299-307. PubMed ID: 4373632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.